glp-1 ra medications found to be safe and effective for treating obesity in adults with mental illness Market Overview: GLP-1 Agonists and

Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes

In addition to helping with insulin resistance, these medications can benefit those with PCOS in other ways: by promoting weight loss, regulating menstrual cycles, reducing chronic inflammation, and lowering the risk of cardiovascular disease and non-alcoholic fatty liver disease, conditions that can be associated with PCOS

GLP-1 RAs significantly reduced the risk of MACE compared with placebo (hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.770.98) in HF coexisting with T2DM

Brand- Name vs

Alcohol Use Disorder (AUD) in the United States: Age Groups and Demographic Characteristic

PMID 16005476